Drug

Disitamab vedotin

In clinical development

ClassTubulin disrupting agentEmerging researchLate-stage development

Also known as RC48-ADC, Vedicitumomab, DisitamabVedotin.

RxNorm2622201 ChEMBLCHEMBL5095273UNIIRB3U3A1S27

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

Clinical trial2026-07-22Results expected Q3 2029 · ClinicalTrials.gov

Neoadjuvant RC48 Plus Gemcitabine for HER2 1~3+ MIBC: A Prospective, Multicenter, Randomized, Controlled, Non-inferiority Study (GUARD-02)

Clinical trial2026-07-09Results expected Q3 2028 · ClinicalTrials.gov

A Prospective, Single-center, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Overexpressing Advanced Gastric Cancer With Disitamab Vedotin in Combination With Cadonilimab

Clinical trial2026-07-06Primary completion · ClinicalTrials.gov

A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)

Clinical trial2026-06-15Results expected Q1 2027 · ClinicalTrials.gov

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Medium-high Risk Non-Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial

Clinical trial2026-06-12Results expected Q2 2027 · ClinicalTrials.gov

A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

A Prospective, Randomized Controlled Study of Perioperative Disitamab Vedotin Plus Immunotherapy Versus Chemotherapy Plus Immunotherapy in Patients With Resectable HER2-Expressing Muscle-Invasive Bladder Cancer (HOPE-07-MIBC Study)

Clinical trial2026-05-27Results expected Q2 2030 · ClinicalTrials.gov

Disitamab Vedotin (RC48-ADC) in Patients With HER2-low Advanced Breast Cancer

Clinical trial2026-05-13Results expected Q4 2026 · ClinicalTrials.gov

An Open-Label, Single-Arm Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Ivonescimab in the Perioperative Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC)

Clinical trial2026-05-01Primary completion · ClinicalTrials.gov

A PHASE 1b/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER

Clinical trial2026-04-21Results expected Q4 2027 · ClinicalTrials.gov

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.

Research2023-11-21Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Disitamab vedotin

Aliases & brands

RC48-ADCVedicitumomabDisitamabVedotin

RxNorm CUI

2622201

ChEMBL ID

CHEMBL5095273

UNII

RB3U3A1S27

Primary mechanism

Tubulin disrupting agent

Pharmacology & targets

16 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tubulin beta-4B chain

TUBB4B · P68371